Hansa Biopharma
0 followers
HNSA
Performance
About Hansa Biopharma
Hansa Biopharma develops antibody-cleaving enzyme therapies that inactivate IgG antibodies to treat rare immunologic diseases. The company focuses on autoimmune conditions, desensitization in transplantation, and enabling lifesaving therapies through its IgG-targeting pipeline, including imlifidase and HNSA-5487. Based in Lund, Sweden, Hansa aims to transform outcomes for patients with highly sensitized immune responses and enable access to therapies affected by IgG antibodies.
Recent News
No recent news for this company.